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effect of treatment characteristics of upper extremity interven-
tions on the decision of tetraplegic subjects to accept treatment.
METHOD: A discrete choice experiment (DCE) was performed,
where treatment characteristics were obtained to establish dif-
ferent treatment scenarios. Seven different treatment character-
istics were obtained from a panel of international experts.
Tetraplegics were offered 20 sets of two different treatment 
scenarios and asked to select the best scenario. RESULTS: A 
total of 47 tetraplegic subjects with C5–6 lesions, motor group
M1–4 were selected. Relative importance of treatment charac-
teristics were: intervention type (surgery or surgery with FES
implant) 13%, number of operations 15%, in patient rehabili-
tation period 22%, ambulant rehabilitation period 9%, compli-
cation rate 15%, improvement of elbow function 10%,
improvement of hand function 15%. Effects of various changes
of treatment protocols were determined. An inpatient rehabili-
tation period of maximum 4 weeks increases preference for
treatment with 32%. One instead of two operative procedures
increases the preference with 25%. CONCLUSION: In-patient
rehabilitation period appears to have the greatest impact on the
decision by patients to have surgery or not. Implantation of a
neural implant is not the main reason for not accepting this type
of treatment.
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OBJECTIVES: The primary objective is to evaluate health, non-
health cost and utilities differences between Parkinson patients
with diagnosis performed through SPECT (Single Proton Emis-
sion Computerized Tomography) and patients diagnosed tradi-
tionally. METHODS: This economic analysis is part of the
prospective, multicentre, observational study DIAPASON (Diag-
nosis of Parkinson’s Disease: Economics and Outcomes Impact),
which involved 17 neurology centers. The present poster presents
the preliminary economic results. Inclusion criteria: all subjects
with suspect parkinsonism, “de novo” patients or in dopamin-
ergic therapy for 3 months at the most. Exclusion criteria: subject
with dementia senile, subjects treated with antidopaminergic
drugs, subjects with iatrogenic forms of disease already known
or clear vascular lesions of substantia nigra or caudato or
putamen. The prospectives used in the study were: national
health system (NHS) and society. Data were collected using an
electronic case report form. Utilities were calculated using the
EuroQol (EQ-5D) questionnaire. RESULTS: In November 2004,
147 patients (50 NO SPECT, 97 SPECT) had already performed
the second visit. For both ﬁrst and second visit the total cost for
patients with diagnosis performed through SPECT was higher
than that obtained for patients diagnosed traditionally: the mean
health cost supported by NHS per patient was €2,577.79
(€1,562.63 for NO SPECT patients and €3,024.00 for SPECT
ones), and mean non health cost obtained per patient was
€3,553.56 (€3923.44 for SPECT patients, €2712.08 for NO
SPECT patients). For subjects diagnosed traditionally the cost
per QALYs gained was €36,225.2 compared to €15,291.6 for
SPECT patients group. CONCLUSION: The introduction of
new technologies, as SPECT, and the use of new radiolabelled
drugs concur to improve early diagnosis of Parkinson’s disease
and related diseases. Diagnosis using SPECT has health and non
health cost higher than traditional diagnosis, but a cost-utility
analysis demonstrate its cost saving role in comparison with tra-
ditional diagnosis.
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OBJECTIVE: Assess the cost-utility of rasagiline, entacapone
and standard care (levodopa) in Parkinson’s disease (PD) patients
with motor ﬂuctuations in Finland. METHODS: A 2-year prob-
abilistic Markov model with 3 health states: £25% off-time/day’,
‘>25% off-time/day’ and ‘dead’ was used. Model inputs included
transition probabilities from randomised clinical trials, utilities
from a preference measurement study and costs and resources
from a Finnish cost-of-illness study. Effectiveness measures were
Quality Adjusted Life Years (QALYs) and number of months
spent with £25% off-time/day. The primary analysis was per-
formed from the societal perspective. Extensive sensitivity and
subgroup analyses on severe patients were performed. A parity
price was assumed for rasagiline and entacapone based on
WHO-DDD. RESULTS: Over 2 years, rasagiline appeared to
show both greater effectiveness and cost reductions compared
with standard care (0.38 additional QALYs, over 55% addi-
tional time spent with £25% off-time/day and €900 savings
(95% CI: [-€3400; €1090]) per treated patient. Rasagiline and
entacapone yielded similar effectiveness and costs. A trend in
favour of rasagiline was observed in the severe patient subgroup
(approximately €660 total cost savings/patient). Sensitivity
analyses conﬁrmed robustness of the results vs. standard care.
Results vs. entacapone were sensitive to changes in transition
probabilities and drug prices. CONCLUSION: This economic
model supports the use of rasagiline as a cost-effective treatment
compared with levodopa alone and combined with entacapone
in PD patients with motor ﬂuctuations in Finland. Further
improvements of the model should be applied to different set-
tings to conﬁrm these results.
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OBJECTIVE: To explore costs and health beneﬁts of replacing
conventional oral therapy with intraduodenal infusion of car-
bidopa/levodopa (Duodopa®) for severe Parkinson’s disease
(PD). METHODS: In the DIREQT trial 24 patients aged 50–79
years with Hoehn & Yahr stage 2.5–4.0 (at best) were ran-
domised to receive either three weeks of conventional oral
therapy followed by three weeks of Duodopa, or vice versa.
Later, patients could choose to switch permanently to Duodopa.
Health Related Quality of Life (HRQOL) was recorded with the
15D instrument at entry into the trial, during the trial, and then
at 8 follow-ups during the subsequent 6 months. Use of health
care was registered before, during and after the trial. Two-year
costs and health consequences of Duodopa and conventional
therapy were estimated in a decision analytic model. Costs were
based on market prices and customary charges in Sweden.
RESULTS: The mean quality-of-life scores were 0.77 for
Duodopa and 0.72 for conventional therapy with considerable
variation in scores for individual patients over time. The
expected two year cost was $93,600 for Duodopa and $28,700
for conventional oral therapy. The expected number of Quality
